CALCIMEDICA INC Financials
This page shows CALCIMEDICA INC (CALC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CalciMedica still operates as a financing-dependent R&D company, with cash preservation driven more by external inflows than by the business itself.
Between FY2024 and FY2025, operating cash use stayed almost unchanged at-$21.1M , yet cash on hand rose to$11.5M because financing and other inflows offset the burn. At the same time, equity swung from$14.4M to-$6.6M and net loss widened to-$29.6M , showing better liquidity did not come from the company becoming self-funding.
The expense mix still looks like a development-stage cost structure: FY2025 R&D spending was
The key balance-sheet nuance is liquidity versus solvency: a 3.6x current ratio and
Financial Health Signals
CALCIMEDICA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CALCIMEDICA INC passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
CALCIMEDICA INC reported a net loss of $29.6M while operations used $21.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
CALCIMEDICA INC reported an operating loss of $23.1M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
CALCIMEDICA INC's EBITDA was -$23.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.4% from the prior year.
CALCIMEDICA INC reported -$29.6M in net income in fiscal year 2025. This represents a decrease of 115.8% from the prior year.
CALCIMEDICA INC earned -$1.97 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 61.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
CALCIMEDICA INC recorded an outflow of $21.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 0.2% from the prior year.
CALCIMEDICA INC held $11.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
CALCIMEDICA INC invested $15.2M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.
CALCIMEDICA INC invested $28K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 250.0% from the prior year.
Not reported for fiscal year 2025.
CALC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $15.2M+5.2% | $14.5M-8.7% | $15.9M+89.9% | $8.3M-55.8% | $18.9M-9.8% | $21.0M-31.5% | $30.6M |
| SG&A Expenses | N/A | $7.9M-18.9% | $9.7M-56.2% | $22.2M+280.2% | $5.8M-65.7% | $17.0M+92.2% | $8.9M+28.1% | $6.9M |
| Operating Income | N/A | -$23.1M+4.5% | -$24.2M+36.4% | -$38.1M-168.3% | -$14.2M+60.5% | -$35.9M-20.5% | -$29.8M+20.5% | -$37.5M |
| Interest Expense | N/A | $1.4M | $0 | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0-100.0% | $1K0.0% | $1K | N/A | N/A | N/A |
| Net Income | N/A | -$29.6M-115.8% | -$13.7M+60.1% | -$34.4M-339.1% | -$7.8M+78.2% | -$35.8M-30.1% | -$27.5M+25.7% | -$37.0M |
| EPS (Diluted) | — | -$1.97-61.5% | -$1.22 | -$7.66 | -$111.16 | -$1.69 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CALC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $13.6M-31.3% | $19.8M+62.4% | $12.2M+263.8% | $3.3M-95.2% | $69.1M-32.1% | $101.8M+150.4% | $40.7M |
| Current Assets | $13.5M-31.2% | $19.7M+69.5% | $11.6M+570.8% | $1.7M-97.4% | $67.1M-32.4% | $99.2M+173.6% | $36.3M |
| Cash & Equivalents | $11.5M+45.2% | $7.9M+43.5% | $5.5M+316.7% | $1.3M-90.1% | $13.4M-60.0% | $33.4M+110.6% | $15.9M |
| Total Liabilities | $20.2M+275.8% | $5.4M+33.7% | $4.0M-94.6% | $74.7M-43.9% | $133.1M+1798.9% | $7.0M-95.1% | $143.6M |
| Current Liabilities | $3.8M+2.7% | $3.7M-8.5% | $4.0M-15.7% | $4.8M+17.8% | $4.1M-42.0% | $7.0M-42.9% | $12.3M |
| Total Equity | -$6.6M-146.1% | $14.4M+76.7% | $8.2M+111.4% | -$71.3M-11.4% | -$64.0M-167.5% | $94.8M+192.1% | -$103.0M |
| Retained Earnings | -$189.3M-18.5% | -$159.8M-9.4% | -$146.1M-30.8% | -$111.7M+34.0% | -$169.2M-26.9% | -$133.4M-26.0% | -$105.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CALC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.1M | -$21.2M-0.2% | -$21.1M+17.8% | -$25.7M-118.8% | -$11.8M+62.7% | -$31.5M+1.8% | -$32.1M-2.7% | -$31.2M |
| Capital Expenditures | $14K | $28K+250.0% | $8K-89.7% | $78K+1850.0% | $4K-99.2% | $488K-52.3% | $1.0M+69.1% | $605K |
| Free Cash Flow | -$19.1M | -$21.2M-0.2% | -$21.2M+18.0% | -$25.8M-119.4% | -$11.8M+63.2% | -$32.0M+3.3% | -$33.1M-4.0% | -$31.8M |
| Investing Cash Flow | $12.2M | $9.6M+315.9% | -$4.4M-149.8% | $8.9M+222200.0% | -$4K-100.0% | $10.8M+125.3% | -$42.6M-106.4% | -$20.6M |
| Financing Cash Flow | $19.6M | $15.2M-45.6% | $28.0M+33.8% | $20.9M+146.6% | $8.5M+1119.6% | $695K-99.2% | $92.2M+68.0% | $54.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CALC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -95.1%+326.1pp | -421.2% | N/A | N/A | -29.0% | N/A |
| Return on Assets | -217.5%-148.3pp | -69.2%+212.8pp | -282.0%-48.3pp | -233.6%-181.8pp | -51.8%-24.8pp | -27.1%+64.0pp | -91.1% |
| Current Ratio | 3.58-1.8x | 5.34+2.5x | 2.88+2.5x | 0.36-16.2x | 16.53+2.4x | 14.18+11.2x | 2.96 |
| Debt-to-Equity | N/A | 0.37-0.1x | 0.49 | N/A | N/A | 0.07 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$6.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where CALCIMEDICA INC Ranks
Frequently Asked Questions
Is CALCIMEDICA INC profitable?
No, CALCIMEDICA INC (CALC) reported a net income of -$29.6M in fiscal year 2025.
What is CALCIMEDICA INC's EBITDA?
CALCIMEDICA INC (CALC) had EBITDA of -$23.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CALCIMEDICA INC's free cash flow?
CALCIMEDICA INC (CALC) recorded an outflow of $21.2M in free cash flow during fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CALCIMEDICA INC's operating cash flow?
CALCIMEDICA INC (CALC) recorded an outflow of $21.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CALCIMEDICA INC's total assets?
CALCIMEDICA INC (CALC) had $13.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are CALCIMEDICA INC's capital expenditures?
CALCIMEDICA INC (CALC) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does CALCIMEDICA INC spend on research and development?
CALCIMEDICA INC (CALC) invested $15.2M in research and development during fiscal year 2025.
What is CALCIMEDICA INC's current ratio?
CALCIMEDICA INC (CALC) had a current ratio of 3.58 as of fiscal year 2025, which is generally considered healthy.
What is CALCIMEDICA INC's return on assets (ROA)?
CALCIMEDICA INC (CALC) had a return on assets of -217.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CALCIMEDICA INC's cash runway?
Based on fiscal year 2025 data, CALCIMEDICA INC (CALC) had $11.5M in cash against an annual operating cash burn of $21.2M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is CALCIMEDICA INC's debt-to-equity ratio negative or not reported?
CALCIMEDICA INC (CALC) has negative shareholder equity of -$6.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is CALCIMEDICA INC's Piotroski F-Score?
CALCIMEDICA INC (CALC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CALCIMEDICA INC's earnings high quality?
CALCIMEDICA INC (CALC) reported a net loss of $29.6M while operations used $21.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CALCIMEDICA INC cover its interest payments?
CALCIMEDICA INC (CALC) reported an operating loss of $23.1M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.